Journal ArticleDOI
Radiofrequency Ablation With or Without Transcatheter Arterial Chemoembolization in the Treatment of Hepatocellular Carcinoma: A Prospective Randomized Trial
Zhenwei Peng,Yaojun Zhang,Minshan Chen,Li Xu,Hui Hong Liang,Xiaojun Lin,Rong Ping Guo,Ya Qi Zhang,Wan Yee Lau +8 more
Reads0
Chats0
TLDR
TACE-RFA was superior to RFA alone in improving survival for patients with HCC less than 7 cm, and on logistic regression analyses, treatment allocation, tumor size, and tumor number were significant prognostic factors for overall survival.Abstract:
Purpose To compare radiofrequency ablation (RFA) with or without transcatheter arterial chemoembolization (TACE) in the treatment of hepatocellular carcinoma (HCC). Patients and Methods A randomized controlled trial was conducted on 189 patients with HCC less than 7 cm at a single tertiary referral center between October 2006 and June 2009. Patients were randomly asssigned to receive TACE combined with RFA (TACE-RFA; n = 94) or RFA alone (n = 95). The primary end point was overall survival. The secondary end point was recurrence-free survival, and the tertiary end point was adverse effects. Results At a follow-up of 7 to 62 months, 34 patients in the TACE-RFA group and 48 patients in the RFA group had died. Thirty-three patients and 52 patients had developed recurrence in the TACE-RFA group and RFA group, respectively. The 1-, 3-, and 4-year overall survivals for the TACE-RFA group and the RFA group were 92.6%, 66.6%, and 61.8% and 85.3%, 59%, and 45.0%, respectively. The corresponding recurrence-free sur...read more
Citations
More filters
Journal ArticleDOI
EASL-EORTC clinical practice guidelines : management of hepatocellular carcinoma
Peter R. Galle,Alejandro Forner,Josep M. Llovet,Vincenzo Mazzaferro,Fabio Piscaglia,Jean-Luc Raoul,Peter Schirmacher,Valérie Vilgrain +7 more
TL;DR: The following Clinical Practice Guidelines will give up-to-date advice for the clinical management of patients with hepatocellular carcinoma, as well as providing an in-depth review of all the relevant data leading to the conclusions herein.
Journal ArticleDOI
Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma.
TL;DR: Studies now aim to identify molecular markers and imaging techniques that can detect patients with HCC at earlier stages and better predict their survival time and response to treatment.
Journal ArticleDOI
Hepatocellular carcinoma: clinical frontiers and perspectives
TL;DR: While several trials have failed to improve the benefits of established therapies, studies assessing the sequential or combined application of those already known to be beneficial are needed to help explain the failure of prior studies.
Journal ArticleDOI
Image-guided Tumor Ablation: Standardization of Terminology and Reporting Criteria—A 10-Year Update
Muneeb Ahmed,Luigi Solbiati,Christopher L. Brace,David J. Breen,Matthew R. Callstrom,J. William Charboneau,Min-hua Chen,Byung Ihn Choi,Thierry de Baere,Gerald D. Dodd,Damian E. Dupuy,Debra A. Gervais,David Gianfelice,Alice Gillams,Fred T. Lee,Edward Leen,Riccardo Lencioni,Peter Littrup,T. Livraghi,David S.K. Lu,John P. McGahan,Maria Franca Meloni,Boris Nikolic,Philippe L. Pereira,Ping Liang,Hyunchul Rhim,Steven C. Rose,Riad Salem,Constantinos T. Sofocleous,Stephen B. Solomon,Michael C. Soulen,Masatoshi Tanaka,Thomas J. Vogl,Bradford J. Wood,S. Nahum Goldberg +34 more
TL;DR: This updated consensus document provides a framework that will facilitate the clearest communication among investigators regarding ablative technologies and improve the precision of communications in this field, leading to more accurate comparison of technologies and results, and ultimately to improved patient outcomes.
Journal ArticleDOI
Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition).
Jian Zhou,Hui-Chuan Sun,Zheng Wang,Wen Ming Cong,Jian-Hua Wang,Meng Su Zeng,Jia Mei Yang,Ping Bie,Lianxin Liu,Tian Fu Wen,Guo Hong Han,Mao Qiang Wang,Rui Bao Liu,Li Gong Lu,Zheng Gang Ren,Minshan Chen,Zhao Chong Zeng,Ping Liang,Changhong Liang,Min Chen,Fu Hua Yan,Wen Ping Wang,Yuan Ji,Wen Wu Cheng,Chao Liu Dai,Wei-Dong Jia,Ya Ming Li,Ye Xiong Li,Jun Liang,Tian Shu Liu,Guo Yue Lv,Yi Lei Mao,Wei Xin Ren,Hong Cheng Shi,Wen Tao Wang,Xiaoying Wang,Bao Cai Xing,Jian Ming Xu,Jian Yong Yang,Ye Fa Yang,Sheng Long Ye,Zheng Yu Yin,Bo Heng Zhang,Shui Jun Zhang,Wei Ping Zhou,Ji Ye Zhu,Rong Liu,Ying Hong Shi,Yong Sheng Xiao,Zhi Dai,Gao Jun Teng,Jian Qiang Cai,Wei Lin Wang,Jia Hong Dong,Qiang Li,Feng Shen,Shu Kui Qin,Jia Fan +57 more
TL;DR: A guideline on the surveillance, diagnosis, staging, and treatment of HCC occurring in China is presented, and recommendations regarding patients with HCC in China are made to ensure optimum patient outcomes.
References
More filters
Journal ArticleDOI
Global cancer statistics
TL;DR: A substantial proportion of the worldwide burden of cancer could be prevented through the application of existing cancer control knowledge and by implementing programs for tobacco control, vaccination, and early detection and treatment, as well as public health campaigns promoting physical activity and a healthier dietary intake.
Journal ArticleDOI
Global cancer statistics, 2002.
TL;DR: There are striking variations in the risk of different cancers by geographic area, most of the international variation is due to exposure to known or suspected risk factors related to lifestyle or environment, and provides a clear challenge to prevention.
Journal ArticleDOI
Management of hepatocellular carcinoma.
Jordi Bruix,Morris Sherman +1 more
TL;DR: The prevention of Cirrhosis can prevent the development of HCC and progression from chronic HCV infection to advanced fibrosis or cirrhosis may be prevented in 40% of patients who are sustained responders to new antiviral strategies, such as pegylated interferon and ribavirin.
Journal ArticleDOI
Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference
Jordi Bruix,Morris Sherman,Josep M. Llovet,Michel Beaugrand,Riccardo Lencioni,Andrew K. Burroughs,Erik Christensen,Luigi Pagliaro,Massimo Colombo,Juan Rodés +9 more
Journal ArticleDOI
Prognosis of hepatocellular carcinoma : the bclc staging classification
TL;DR: A new staging system is proposed, the Barcelona Clinic Liver Cancer (BCLC) staging classification, that comprises four stages that select the best candidates for the best therapies currently available, based on prognostic factors obtained from studies performed years ago.
Related Papers (5)
Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival
Josep M. Llovet,Jordi Bruix +1 more
Sorafenib in Advanced Hepatocellular Carcinoma
Josep M. Llovet,Sergio Ricci,Vincenzo Mazzaferro,Philip Hilgard,Edward Gane,Jean-Frédéric Blanc,André Cosme de Oliveira,Armando Santoro,Jean-Luc Raoul,Alejandro Forner,Myron Schwartz,Camillo Porta,Stefan Zeuzem,Luigi Bolondi,Tim F. Greten,Peter R. Galle,Jean Francois Seitz,Ivan Borbath,Dieter Häussinger,Tom Giannaris,Minghua Shan,M. Moscovici,D. Voliotis,Jordi Bruix +23 more